Pfizer Inc (PFE)
40.45
+0.44 (+1.10%)
USD |
NYSE |
Mar 23, 13:06
Pfizer Research and Development Expense (Annual): 11.43B for Dec. 31, 2022
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
Date | Value |
---|---|
December 31, 2022 | 11.43B |
December 31, 2021 | 10.36B |
December 31, 2020 | 9.393B |
December 31, 2019 | 8.385B |
December 31, 2018 | 7.76B |
December 31, 2017 | 7.683B |
December 31, 2016 | 7.892B |
December 31, 2015 | 7.69B |
December 31, 2014 | 8.393B |
December 31, 2013 | 6.678B |
December 31, 2012 | 7.482B |
December 31, 2011 | 8.681B |
December 31, 2010 | 9.483B |
December 31, 2009 | 7.845B |
Date | Value |
---|---|
December 31, 2008 | 8.578B |
December 31, 2007 | 8.089B |
December 31, 2006 | 7.599B |
December 31, 2005 | 7.256B |
December 31, 2004 | 7.513B |
December 31, 2003 | 7.487B |
December 31, 2002 | 5.208B |
December 31, 2001 | 4.776B |
December 31, 2000 | 4.435B |
December 31, 1999 | 4.036B |
December 31, 1998 | 3.305B |
December 31, 1997 | 1.805B |
December 31, 1996 | 1.567B |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
7.76B
Minimum
2018
11.43B
Maximum
2022
9.465B
Average
9.393B
Median
2020
Research and Development Expense (Annual) Benchmarks
ORIC Pharmaceuticals Inc | 61.68M |
Moderna Inc | 3.295B |
Amgen Inc | 4.434B |
Gilead Sciences Inc | 4.977B |
Johnson & Johnson | 15.39B |